A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 402 participants.

Also called NCT06431763

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 402 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06431763
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06431763. Randomized; no masking; primary purpose treatment. Start 2024-06-21 (actual); primary completion 2025-12-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.
Condition
Hypercholesterolemia
Intervention (Drug)
Inclisiran sodium
Intervention (Drug)
BPA
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06431763
Content hash
dd8c92cd8904c784b4fa78f47d54c7440c8bc2415a284410ad6a6cba83c98351